Investment House LLC Lowers Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Investment House LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,265 shares of the medical research company’s stock after selling 3,041 shares during the period. Investment House LLC’s holdings in Charles River Laboratories International were worth $12,048,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc raised its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Assetmark Inc. increased its holdings in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International during the third quarter worth about $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research analyst reports. UBS Group restated a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $191.31.

Charles River Laboratories International Trading Up 1.1 %

Shares of Charles River Laboratories International stock opened at $177.02 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The firm has a market cap of $9.05 billion, a PE ratio of 1,180.13, a PEG ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a 50 day simple moving average of $167.21 and a two-hundred day simple moving average of $184.18.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the business posted $2.46 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).